- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06260722
Virkning af retatrutide sammenlignet med Semaglutid hos voksne deltagere med type 2-diabetes og utilstrækkelig glykæmisk kontrol med metformin med eller uden SGLT2-hæmmer (TRANSCEND-T2D-2)
Et fase 3, randomiseret, multicenter, åbent studie for at undersøge effektiviteten og sikkerheden af Retatrutide én gang om ugen sammenlignet med Semaglutid én gang om ugen hos voksne deltagere med type 2-diabetes og utilstrækkelig glykæmisk kontrol med metformin med eller uden SGLT2-hæmmer (TRANSCEND-T2D- 2)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1056ABI
- Centro de Investigaciones Metabólicas (CINME)
-
Buenos Aires, Argentina, C1426ABP
- Fundación Respirar
-
Córdoba, Argentina, 5000
- Centro Diabetológico Dr. Waitman
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 1414
- CARE - Centro de Alergia y Enfermedades Respiratorias
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentina, C1425AGC
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
-
Buenos Aires, Buenos Aires F.D., Argentina, C1061AAS
- CIPREC
-
Buenos Aires, Buenos Aires F.D., Argentina, C1023AAB
- Stat Research S.A.
-
Buenos Aires, Buenos Aires F.D., Argentina, C1120AAC
- Centro Médico Viamonte
-
Buenos Aires, Buenos Aires F.D., Argentina, C1128AAF
- Mautalen Salud e Investigación
-
C.a.b.a., Buenos Aires F.D., Argentina, C1205AAO
- CEMEDIAB
-
CABA, Buenos Aires F.D., Argentina, 1204
- Instituto Centenario
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentina, 5006
- Centro Medico Privado San Vicente Diabetes
-
-
Mendoza Province
-
Godoy Cruz, Mendoza Province, Argentina, 5501
- CIPADI - Centro Integral de Prevencion y Atencion en Diabetes
-
-
Santa Fe Province
-
Granadero Baigorria, Santa Fe Province, Argentina, 2152
- Centro de Investigaciones Clínicas Baigorria
-
Rosario, Santa Fe Province, Argentina, S2000CVD
- Instituto de Investigaciones Clinicas Rosario
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2T 5C7
- University of Calgary - Clinical Trials Unit
-
Edmonton, Alberta, Canada, T6G 2E1
- Alberta Diabetes Institute
-
-
Ontario
-
Brampton, Ontario, Canada, L6T 0G1
- Aggarwal and Associates Limited
-
Brampton, Ontario, Canada, L6S 0C6
- Centricity Research Brampton Endocrinology
-
Hamilton, Ontario, Canada, L8J 0B6
- Winterberry Research Inc.
-
Hamilton, Ontario, Canada, L8L 5G8
- The Wharton Medical Clinic Clinical Trials Inc
-
Hamilton, Ontario, Canada, L8L5G4
- Hamilton Medical Research Group
-
Sarnia, Ontario, Canada, N7T 4X3
- Bluewater Clinical Research Group Inc.
-
Toronto, Ontario, Canada, M4S 1Y2
- Prime Health Clinical Research
-
Toronto, Ontario, Canada, M5G 1K2
- Maple Leaf Research
-
Whitby, Ontario, Canada, L1N 2L1
- Private Practice - Dr. Nigel Jagan
-
-
Quebec
-
Montreal, Quebec, Canada, H4N 2W2
- 9109-0126 Quebec Inc.
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- University of Alabama - Department of Nutrition Sciences
-
-
California
-
Escondido, California, Forenede Stater, 92025
- Neighborhood Healthcare Institute of Health
-
Long Beach, California, Forenede Stater, 90805
- Long Beach Research Institute
-
Northridge, California, Forenede Stater, 91325
- Valley Clinical Trials, Inc.
-
Rancho Cucamonga, California, Forenede Stater, 91730
- Rancho Cucamonga Clinical Research
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado Anschutz Medical Campus
-
-
Florida
-
Daytona Beach, Florida, Forenede Stater, 32117
- Arrow Clinical Trials
-
Miami, Florida, Forenede Stater, 33186
- New Age Medical Research Corporation
-
Miramar, Florida, Forenede Stater, 33027
- South Broward Research
-
Winter Haven, Florida, Forenede Stater, 33880
- Clinical Research of Central Florida
-
-
Georgia
-
Suwanee, Georgia, Forenede Stater, 30024
- Herman Clinical Research
-
Woodstock, Georgia, Forenede Stater, 30189
- North Georgia Clinical Research
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96817
- Pacific Diabetes & Endocrine Center
-
-
Idaho
-
Idaho Falls, Idaho, Forenede Stater, 83404
- Rocky Mountain Clinical Research
-
-
Indiana
-
Newburgh, Indiana, Forenede Stater, 47630
- Deaconess Clinic - Gateway Health Center
-
-
Louisiana
-
Monroe, Louisiana, Forenede Stater, 71201
- IMA Clinical Research Monroe - Armand
-
-
Maryland
-
Hyattsville, Maryland, Forenede Stater, 20782
- MedStar Health Research Institute (MedStar Physician Based Research Network)
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Brigham and Women's Hospital Diabetes Program
-
Fall River, Massachusetts, Forenede Stater, 02721
- NECCR PrimaCare Research
-
-
Michigan
-
Troy, Michigan, Forenede Stater, 48098
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89148
- Palm Research Center Sunset
-
Las Vegas, Nevada, Forenede Stater, 89128
- Palm Research Center Tenaya
-
-
New York
-
Long Island City, New York, Forenede Stater, 11106
- NYC Research INC
-
-
North Carolina
-
Greensboro, North Carolina, Forenede Stater, 27405
- Medication Management
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43215
- Remington Davis Clinical Research
-
-
Oklahoma
-
Norman, Oklahoma, Forenede Stater, 73069
- Alliance for Multispecialty Research, LLC
-
Tulsa, Oklahoma, Forenede Stater, 74136
- Central States Research
-
-
Oregon
-
Corvallis, Oregon, Forenede Stater, 97330
- The Corvallis Clinic, P.C.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Thomas Jefferson University Hospital
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75230
- Velocity Clinical Research, Dallas
-
Fort Worth, Texas, Forenede Stater, 76164
- Valley Institute of Research - Fort Worth
-
Houston, Texas, Forenede Stater, 77040
- Juno Research
-
Mesquite, Texas, Forenede Stater, 75149
- Southern Endocrinology Associates
-
Shavano Park, Texas, Forenede Stater, 78231
- Consano Clinical Research, LLC
-
Weslaco, Texas, Forenede Stater, 78596
- Texas Valley Clinical Research
-
Wylie, Texas, Forenede Stater, 75098
- Medrasa Clinical Research
-
-
Washington
-
Wenatchee, Washington, Forenede Stater, 98801
- Central Washington Health Services Association d/b/a Confluence Health
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater, 26505
- IMA Clinical Research West Virginia
-
-
-
-
-
Chihuahua City, Mexico, 31110
- Enclifar Ensayos Clínicos Farmacológicos Sc
-
Veracruz, Mexico, 91851
- Instituto Veracruzano en Investigación Clínica S.C.
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44130
- Diseno y Planeacion en Investigacion Medica
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 11650
- Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
-
Mexico City, Mexico City, Mexico, 03100
- RM Pharma Specialists
-
Mexico City, Mexico City, Mexico, 06090
- Hospital de Jésus, I.A.P.
-
-
Morelos
-
Cuernavaca, Morelos, Mexico, 62250
- Instituto de Diabetes, Obesidad y Nutricion
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 66460
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
-
Monterrey, Nuevo León, Mexico, 64610
- Clínica García Flores SC
-
Monterrey, Nuevo León, Mexico, 64060
- Cardiolink Clin Trials
-
-
-
-
-
Bayamón, Puerto Rico, 00959
- Advanced Clinical Research, LLC
-
San Juan, Puerto Rico, 00917
- GCM Medical Group, PSC - Hato Rey Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Have Type 2 Diabetes (T2D)
- Have HbA1c ≥ 7.0% (53 millimoles per mole (mmol/mol)) to ≤ 10.5% (91 mmol/mol)
- Have been on a stable diabetes treatment consisting of metformin ≥ 1500 milligrams per day (mg/day) with or without SGLT2i during 90 days prior to screening
- Are of stable weight for at least 90 days prior to screening
- Have a Body Mass Index (BMI) ≥ 25.0 kilograms per meter squared (kg/m^2)
Exclusion Criteria:
- Have Type 1 Diabetes (T1D)
- Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening
- Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
- Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
- Have an estimated glomerular filtration rate (eGFR) <45 milliliters/minute/1.73 meter squared (mL/min/1.73 m^2) or lower than the country-specific threshold for discontinuing metformin therapy per local label as determined by the central laboratory
- Have a prior or planned surgical treatment for obesity
- Have New York Heart Association Functional Classification IV congestive heart failure
- Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening
- Have a known clinically significant gastric emptying abnormality
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
- Have any lifetime history of a suicide attempt
- Had chronic or acute pancreatitis
- Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2
- Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Retatrutide Dose Level 1
Participants will receive retatrutide administered subcutaneously (SC). |
Administered SC.
Andre navne:
|
|
Eksperimentel: Retatrutide Dose Level 2
Participants will receive retatrutide administered SC. |
Administered SC.
Andre navne:
|
|
Aktiv komparator: Semaglutide
Participants will receive semaglutide administered SC. |
Administered SC. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring fra baseline i hæmoglobin A1c (HbA1c) (%)
Tidsramme: Baseline, uge 80
|
Baseline, uge 80
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring fra baseline i systolisk blodtryk (SBP)
Tidsramme: Baseline, uge 80
|
Baseline, uge 80
|
|
Ændring fra baseline i HbA1c (%)
Tidsramme: Baseline, uge 80
|
Baseline, uge 80
|
|
Procentdel af deltagere, der opnår HbA1c ≤ 6,5 %
Tidsramme: Uge 80
|
Uge 80
|
|
Procentdel af deltagere, der opnår HbA1c < 5,7 %
Tidsramme: Uge 80
|
Uge 80
|
|
Procent ændring fra baseline i kropsvægt
Tidsramme: Uge 80
|
Uge 80
|
|
Ændring fra baseline i kropsvægt
Tidsramme: Baseline, uge 80
|
Baseline, uge 80
|
|
Procentdel af deltagere, der opnår vægtreduktion på ≥ 5 %
Tidsramme: Uge 80
|
Uge 80
|
|
Procentdel af deltagere, der opnår vægtreduktion på ≥ 10 %
Tidsramme: Uge 80
|
Uge 80
|
|
Procentdel af deltagere, der opnår vægtreduktion på ≥ 15 %
Tidsramme: Uge 80
|
Uge 80
|
|
Procentdel af deltagere, der opnår HbA1c ≤ 6,5 % og ≥ 10 % vægtreduktion
Tidsramme: Uge 80
|
Uge 80
|
|
Procent ændring fra baseline i triglycerider
Tidsramme: Uge 80
|
Uge 80
|
|
Procent ændring fra baseline i non-high-density lipoprotein (HDL) kolesterol
Tidsramme: Uge 80
|
Uge 80
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 18805
- J1I-MC-GZBZ (Anden identifikator: Eli Lilly and Company)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-delingstidsramme
Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD-delingsadgangskriterier
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .